# Episode 55. ASH 2024 Myeloma Updates with Dr. Rakesh Popat

Page: https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-55-ash-2024-myeloma-updates-with-dr-rakesh-popat
Text version: https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-55-ash-2024-myeloma-updates-with-dr-rakesh-popat.md
Podcast: [Blood Cancer Talks](https://stenobird.com/podcast/blood-cancer-talks-5570002)
Published: 2025-01-11T13:00:00+00:00
Episode link: https://share.transistor.fm/s/5a007577
Audio file: https://media.transistor.fm/5a007577/9f3caaba.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-55-ash-2024-myeloma-updates-with-dr-rakesh-popat
Duration seconds: 2306

## Resource

In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed: 1. AQUILA Trial in High-Risk SMM Overview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring. Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara. Insights into modes of progression, adequacy of active surveillance, and post-protocol therapy in control arm. Read the abstract . Read the simultaneous publication at NEJM . 2. Anito-Cel: New BCMA CAR T Therapy Early data from the iMMagine-1 trial showing strong efficacy and a promising safety profile for Anito-Cel, a novel BCMA CAR T. Discussion of its potential to rival cilta-cel while avoiding neurotoxicity concerns. Read the abstract . 3. CARTITUDE-4 Update Updates on MRD-negativity rates and survival outcomes for cilta-cel in relapsed myeloma, with significant benefits over standard care. Read the abstract . 4. ANDROMEDA OS Data in AL Amyloidosis Long-term data showing an overall survival (OS) benefit of Dara-VCd over VCd in AL amyloidosis. Insights into cardiac responses and crossover impact. Read the abstract . 5. OPTIMUM Trial in Ultra-High-Risk NDMM Five-year follow-up of a tailored approach for ultra-high-risk newly diagnosed myeloma patients with continuous therapy incorporating multiple active agents. Subgroup outcomes highlighting both challenges and exceptional results. Read the abstract 6. GMMG-HD7 Trial PFS Update Phase 3 trial results on Isa-VRD vs. VRD induction and risk-adapted tandem ASCT. Discussion on the role of CD38 in maintenance therapy. Read the abstract Read the simultaneo…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-55-ash-2024-myeloma-updates-with-dr-rakesh-popat/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-55-ash-2024-myeloma-updates-with-dr-rakesh-popat.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.